Drug intelligence / Profile preview

Micobao

Development stage: Unknown
Modality: Small Molecules
Administration: Oral, Intramuscular, Intravenous

Overview

Micobao (弥可保) is a pharmaceutical drug that contains Mecobalamin, an active form of Vitamin B12. It is primarily used for the treatment of peripheral neuropathy and megaloblastic anemia caused by Vitamin B12 deficiency. The drug functions by supporting nerve repair, enhancing red blood cell production, and promoting overall nerve function. Its mechanism involves acting as a coenzyme in methionine synthesis, facilitating nucleic acid and protein synthesis within nerve cells, promoting axonal transport and regeneration, and contributing to myelin formation. Micobao is manufactured by companies such as Eisai (China) Pharmaceutical Co., Ltd.

Brand names: Methycobal弥可保
Other names: Mecobalamin甲钴胺

Targets

MTR (Methionine synthase)

Beyond the preview

Go deeper on Micobao.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Micobao.

Explore the full profile